<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01670929</url>
  </required_header>
  <id_info>
    <org_study_id>PPROURM</org_study_id>
    <nct_id>NCT01670929</nct_id>
  </id_info>
  <brief_title>Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's Health University Hospital, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Woman's Health University Hospital, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In women with unexplained recurrent miscarriages, progesterone (400 mg pessaries, twice
      daily), started soon as possible at luteal phase and after a positive pregnancy test and
      continued to 28 weeks of gestation, compared to placebo, ).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progesterone improves secondary outcomes such as gestation at delivery, on-going pregnancy at
      12 weeks, survival at 28 days of neonatal life.

      . Progesterone, compared to placebo, does not incur substantial adverse effects to the mother
      or the neonate.

      Explore differential or subgroup effects of progesterone in prognostic subgroups.

      . Perform an economic evaluation for cost-effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients continued the pregnancy beyond 20 weeks gestation.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of miscarriages</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Live Birth</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of preterm delivery</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Abortion, Habitual</condition>
  <arm_group>
    <arm_group_label>Progesterone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>progesterone (400 mg pessary, once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (pessary, once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <arm_group_label>Progesterone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women with unexplained recurrent miscarriages (2 or more consecutive first trimester
             miscarriages).

          2. Age 18-39 years at randomisation (likelihood of miscarriages due to chromosomal
             aberrations is higher in older women; such miscarriages are unlikely to be prevented
             by progesterone therapy).

          3. Spontaneous conception (as confirmed by urinary pregnancy tests).

          4. Willing and able to give informed consent.

        Exclusion Criteria:

          1. Age less than twenty or above forty years old.

          2. Antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies [IgG
             or IgM]); other recognised thrombophilic conditions (testing according to usual clinic
             practice)

          3. Intrauterine abnormalities (as assessed by ultrasound, hysterosonography,
             hysterosalpingogram, or hysteroscopy).

          4. Fibroids distorting uterine cavity.

          5. Abnormal parental karyotype.

          6. Other identifiable causes of recurrent miscarriages (tests initiated only if
             clinically indicated) e.g., diabetes, thyroid disease and systemic lupus erythematosus
             (SLE).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alaa M Ismail, M D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculity of medicine,Assiut university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health Hospital</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2012</study_first_submitted>
  <study_first_submitted_qc>August 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2012</study_first_posted>
  <last_update_submitted>April 3, 2016</last_update_submitted>
  <last_update_submitted_qc>April 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's Health University Hospital, Egypt</investigator_affiliation>
    <investigator_full_name>alaa eldeen mahmoud ismail</investigator_full_name>
    <investigator_title>M D</investigator_title>
  </responsible_party>
  <keyword>recurrent miscarriages</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

